Over the last two decades the outcomes of patients with amyloidosis have substantially improved with timely diagnosis, the use of chemotherapeutic agents and improved patient selection for autologous stem cell transplantation (ASCT); however, for patients who are diagnosed at later stages or who are ineligible for ASCT the prognosis is poorer. Recently, the introduction of daratumumab has shown promising results for patients with both newly diagnosed and relapsed/refractory amyloidosis and there have been a number of Phase II/III trials aiming to help guide treatment decision-making and improve patient outcomes.
In today’s podcast, Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, gives an overview of key updates in the treatment landscape of amyloidosis, as presented at the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
CAR-T in the CLL space
CAR T-cell therapy & multiple myeloma: past, present & future
Harnessing the tumor microenvironment in lymphoma therapy
Induction therapy in myeloma: an ever-changing paradigm
Precision epigenetic therapy for B-cell lymphoma
Acute leukemia: pushing boundaries in disease management
iwAL 2019: looking to the future of acute leukemia therapy
CAR T-cell therapy and precision medicine in non-Hodgkin lymphoma
MRD testing in multiple myeloma: new technology with promising clinical applications
CAR T-cells in myeloma: exploratory targets, payment models & treatment sequence
Patient discussion at EHA 2018: CAR T-cells and MRD in CLL
CLL therapies today: novel agents, combinations & the future of the field
CAR T-cell therapy: where are we now and what’s in store for the future?
Focus on MRD: current landscape and future questions in hemonc
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
Acute leukemias: is MRD already a surrogate for survival?
Revolutionary immunotherapies for lymphoma
Latest advances and current challenges in immunotherapies for lymphoma
The circle of CLL: from gene discovery to targeted treatment
Debate on the use of MRD for multiple myeloma management
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive